Nautilus Biotechnology Stock News

Nautilus Biotechnology, Inc. faces reflexivity risks and macroeconomic challenges, but its commercial plan starts next year with substantial cash reserves. Trading below cash value, Nautilus' patents and bio-informatics platform are not being given too much credit by markets. Although, they seem to expect that company to be minimally viable once they have an additional $30 million of cash, whic...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brenn...

Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research's esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging

SEATTLE, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Inaugural Guggenheim Healthcare Conference.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan ...